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ABSTRACT
Objectives To evaluate efﬁcacy and safety of three
different regimens of denosumab, a fully human
monoclonal antibody to receptor activator of nuclear
factor kappa B (RANK) ligand (RANKL), for Japanese
patients with rheumatoid arthritis (RA).
Methods In this multicentre, randomised, placebo-
controlled phase II study, 350 Japanese patients with RA
between 6 months and <5 years, stratiﬁed by
glucocorticoid use and rheumatoid factor status, were
randomly assigned to subcutaneous injections of placebo
or denosumab 60 mg every 6 months (Q6M), every
3 months (Q3M) or every 2 months (Q2M). All patients
basically continued methotrexate treatment and had a
supplement of calcium and vitamin D throughout the
study. The primary endpoint was change in the modiﬁed
Sharp erosion score from baseline to 12 months.
Results Denosumab signiﬁcantly inhibited the
progression of bone erosion at 12 months compared
with the placebo, and the mean changes of the
modiﬁed Sharp erosion score at 12 months from baseline
were 0.99, 0.27 (compared with placebo, p=0.0082),
0.14 (p=0.0036) and 0.09 (p<0.0001) in the placebo,
Q6M, Q3M and Q2M, respectively. Secondary endpoint
analysis revealed that denosumab also signiﬁcantly
inhibited the increase of the modiﬁed total Sharp score
compared with the placebo, with no obvious evidence of
an effect on joint space narrowing for denosumab. As
shown in previous studies, denosumab increased bone
mineral density. No apparent difference was observed in
the safety proﬁles of denosumab and placebo.
Conclusions Addition of denosumab to methotrexate
has potential as a new therapeutic option for patients
with RA with risk factors of joint destruction.
Trial registration number JapicCTI-101263.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic disease char-
acterised by persistent synovitis, systemic inﬂamma-
tion and joint destruction.1 Increased osteoclast
activity contributes to bone erosion and bone loss.2
receptor activator of nuclear factor kappa B
(RANK) ligand (RANKL) is essential for osteoclast
differentiation, activation and survival.3–6
Denosumab is a fully human monoclonal anti-
body that binds speciﬁcally to human RANKL and
inhibits bone resorption.7 This inhibition by deno-
sumab is expected to inhibit the progression of
bone erosion and bone loss.
A phase II study of denosumab in patients with
RA on methotrexate treatment was conducted in
the USA and Canada.8 Denosumab 60 or 180 mg
was administered to subjects every 6 months in this
study. Denosumab inhibited the progression of
bone erosions and systemic bone loss, compared
with placebo. However, denosumab has not been
studied extensively in Japanese patients with RA.
Furthermore, the efﬁcacy and safety of more fre-
quent administration of denosumab had not been
examined. Therefore, we conducted a clinical study
including three different administration regimens of
denosumab in Japanese patients with RA.
METHODS
Patients and study design
This multicentre, randomised, double-blind,
placebo-controlled, phase II study in Japan was
conducted over 12 months. Japanese patients who
had RA were randomised in a 1:1:1:1 ratio to
receive one of four treatments, a placebo, denosu-
mab 60 mg every 6 months (Q6M), denosumab
60 mg every 3 months (Q3M) or denosumab
60 mg every 2 months (Q2M). Randomisation was
stratiﬁed by glucocorticoid use and rheumatoid
factor (RF) status at baseline. Eligible patients were
randomly assigned by a central registration method
using a computer-generated randomisation list pro-
vided by an independent biostatistician. Treatment
was masked to patients, investigators and sponsor
until unblinding. All patients were subcutaneously
administered placebo or denosumab at 0, 2, 3, 4, 6,
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8, 9 and 10 months. All patients basically continued methotrex-
ate treatment, and were given vitamin D ≥400 IU and calcium
≥600 mg per day throughout the study. The investigators could
change the dosage of methotrexate within approved dosages in
Japan (6–16 mg/week) and could use bucillamine, salazosulfa-
pyridine, glucocorticoid and/or non-steroidal anti-inﬂammatory
drugs at any time throughout the study. Eligible patients were
outpatients who were diagnosed with RA based on the
American College of Rheumatology (ACR) criteria.9 Main inclu-
sion criteria were: disease duration of RA between 6 months
and <5 years, 20–74 years old, use of methotrexate for at least
8 weeks prior to ﬁrst investigational product (IP) administration
and conﬁrmed at least 6 swollen joints among 58 joints at the
screening by investigator assessment. Enrolment also required
the presence of bone erosion as assessed by the investigator on
radiographs or meeting the following criteria at a screening: C-
reactive protein (CRP) ≥1.0 mg/dL or erythrocyte sedimentation
rate ≥28 mm/h and positive for anticyclic citrullinated peptide
antibodies or RF>20 IU/mL. Main exclusion criteria were: clas-
siﬁed RA functional status as class IV10 and previous or current
treatment with any biologics for RA treatment. Bisphosphonate
use and the use of oral glucocorticoid >10 mg/day (prednisol-
one equivalent) were prohibited throughout the study.
Study assessments
Radiographs at baseline, 6 and 12 months were submitted to the
central analysing centre (Synarc, California, USA). This centre
evaluated radiographs by the van der Heijde-modiﬁed Sharp
method.11 Clinical assessments recorded at baseline, 6 and
12 months included the following: physician’s global assessment
of disease activity by visual analogue scale (VAS), subject’s
assessment of pain by VAS and the Health Assessment
Questionnaire Disability Index (HAQ-DI).12 Clinical assess-
ments recorded at baseline, 3, 6 and 12 months included the
following: patient’s global assessment of disease activity by VAS,
66-joint count for swollen joints and 68-joint count for tender
joints. Dual energy X-ray absorptiometry (DXA) scans of the
lumbar spine (LS) and total hip (TH) were performed at base-
line, 6 and 12 months. DXA instruments manufactured by
Hologic or GE Healthcare were used. Quality control and ana-
lysis of bone mineral density (BMD) were performed by the
centre (Synarc, Oregon, USA). All DXA machines were stable
throughout the study. Serum and urine samples for evaluation
of bone turnover markers (BTMs) and cartilage markers were
collected at baseline, 1, 2, 3, 4, 6 and 12 months, which were
analysed at a central laboratory (Mitsubishi Chemical Medience,
Tokyo, Japan). Measured biomarkers were the following: (1)
serum markers, including C-telopeptide of type I collagen
(CTX-I), N-propeptide of type I collagen (PINP) and cartilage
oligomeric matrix protein (COMP). (2) urine C-telopeptide of
type II collagen (CTX-II). Patients had fasted for at least 10 h
prior to the collections. The urine sample was collected from
the second urine of the day. CTX-II was adjusted for creatinine
(CTX-II/Cre).
Blood and urine samples were obtained at baseline, 1, 2, 3, 4,
6, 7 and 12 months for haematology, blood biochemistry and
urine tests. These were measured at the central laboratory.
Anti-denosumab antibodies were assessed at baseline, 1, 6 and
12 months by PPD Development (Virginia, USA).
Blood samples for pharmacokinetics were obtained prior to
the IP dosing at baseline, 1, 2, 3, 4, 6, 7, 8, 9, 10 and
12 months. The serum concentrations of denosumab were mea-
sured by PPD Development.
The primary endpoint was the change from the baseline in
the modiﬁed Sharp erosion score at 12 months. Secondary end-
points included change from the baseline in the modiﬁed Sharp
erosion score at 6 months, change from the baseline in the
modiﬁed Sharp joint space narrowing ( JSN) score and the
modiﬁed total Sharp score (TSS) at 6 and 12 months and
percent change from the baseline in BMD at the LS and TH at
6 and 12 months. Exploratory evaluations included the propor-
tion of subjects with disease progression according to the
erosion score, JSN score or TSS by the modiﬁed Sharp method,
the proportion of patients achieving ACR20/50/70 response,13
change from the baseline in HAQ-DI, change from the baseline
in the disease activity score 28 CRP (DAS28-CRP), percent
changes from the baseline in BTMs and cartilage markers and
percent change of BMD from the baseline in the subgroup of
subjects with glucocorticoid use at baseline.
Statistical analyses
A sample size of 80 patients per group was calculated to have
approximately 80% power to detect the dosing interval depend-
ency and plateaued efﬁcacy at denosumab Q3M for the primary
endpoint. This calculation assumed that a difference between
denosumab Q3M group and placebo group of −1.5, an SD of 3
and an early discontinuation rate of 10%. To control the family-
wise type I error for multiple comparisons, comparisons between
the denosumab groups and the placebo group were tested in a
step-down manner using the Shirley–Williams test14 15 at a 0.025
one-sided signiﬁcance level. The same analysis was conducted for
the other endpoint of radiographic score change. In post-hoc
analyses, comparisons among denosumab groups were conducted
using the two-sided van Elteren stratiﬁed rank test adjusted for
randomised strata. The proportions of patients with no disease
progression (the radiographic score change from the baseline ≤0)
and ACR20/50/70 were analysed using a Cochran–Mantel–
Haenszel test adjusting for randomised strata. For changes from
the baseline in DAS28-CRP and HAQ-DI and percent changes
from the baseline in BMD, comparisons of each denosumab
group with the placebo group were performed using the repeated
measures model adjusted for the treatment, visit, baseline value,
randomised strata and treatment-by-visit interaction. In post-hoc
analyses, comparisons among denosumab groups for BMD
percent changes from the baseline were conducted using the
same repeated measures analysis. In the subgroup analysis, the
BMD percent changes from the baseline were assessed by base-
line glucocorticoid use (present/absent) using the same analysis.
Comparisons of each denosumab group with the placebo group
for percent changes from the baseline in BTMs, COMP and
CTX-II/Cre by time point were analysed based on the two-sided
van Elteren stratiﬁed rank test adjusted for randomised strata.
Efﬁcacy endpoints were analysed using a full analysis set (FAS),
which included all randomised patients who received at least one
dose of the IP and had a baseline and at least one postbaseline
radiographic score. Missing values for the radiographic score
were imputed using linear extrapolation/interpolation. For the
other variables, no imputation was implemented. These imput-
ation methods were used in the FAS.
Pharmacokinetic parameters following 0 and 6 months doses,
including area under the serum concentration–time curve up to
the last quantiﬁable time (AUClast), maximum serum concentra-
tion (Cmax), time to reach Cmax (tmax) and observed cumulative
coefﬁcient (deﬁned as the 6-month:0-month ratio of AUC
during dosing interval), were calculated using a non-
compartmental pharmacokinetic analysis method. The pharma-
cokinetic analysis was conducted using the FAS that had at least
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one serum denosumab concentration following administration
of the IP.
RESULTS
Baseline characteristics and patient disposition
Patient disposition is shown in ﬁgure 1.
Baseline demographics and characteristics were generally
comparable between the treatment groups (table 1). However,
the placebo group included slightly more females, patients aged
≥65 years and concomitant osteoporosis compared with the
other groups. The osteoporosis was diagnosed by the investiga-
tors at each site.
Efﬁcacy
The changes from the baseline in the modiﬁed Sharp erosion
score at 12 months as the primary endpoint were signiﬁcantly
lower in the denosumab groups than in the placebo group
(ﬁgure 2A). The mean changes at 12 months from baseline were
0.99 (95% CI 0.42 to 1.56), 0.27 (0.06 to 0.48, compared with
placebo, p=0.0082), 0.14 (0.02 to 0.26, p=0.0036) and 0.09
(−0.24 to 0.41, p<0.0001) in the placebo, Q6M, Q3M and
Q2M, respectively. Changes from the baseline in the modiﬁed
Sharp erosion score at 6 months were also signiﬁcantly lower in
the denosumab groups than that in the placebo group
(p=0.0169, 0.0026 and <0.0001, respectively). The changes
from the baseline in the modiﬁed Sharp JSN score at 6 and
12 months showed no signiﬁcant difference between the deno-
sumab groups and placebo group (ﬁgure 2B). The changes from
the baseline in the modiﬁed TSS at 12 months were signiﬁcantly
lower in the denosumab groups than in the placebo group
(p=0.0185, 0.0046 and 0.0001, respectively; ﬁgure 2C). At
6 months, only the Q2M group showed a signiﬁcantly lower
result compared with the placebo group (p=0.0054).
Cumulative probability plots for changes in the modiﬁed Sharp
erosion score, modiﬁed Sharp JSN score and modiﬁed TSS at
12 months are shown in ﬁgure 3. Proportions of the patients
with no disease progression in the modiﬁed Sharp erosion score
at 12 months were 62.5% (55/88), 78.8% (67/85, compared
with placebo, p=0.0173), 80.5% (66/82, p=0.0099) and
83.5% (71/85, p=0.0019), respectively.
In ACR20/50/70 response rates, denosumab showed no statis-
tical differences compared with the placebo except for the
ACR20 response at 12 months in Q2M (p=0.0473) and the
ACR20 response at 6 months in both Q3M (p=0.0047) and
Q2M (p=0.0198; see online supplementary ﬁgure S1). No sig-
niﬁcant differences in DAS28-CRP and HAQ-DI were con-
ﬁrmed between the denosumab and placebo groups (see online
supplementary ﬁgure S2 and S3).
All denosumab groups signiﬁcantly increased BMD at the LS
and TH compared with the placebo group at 6 and 12 months
(p<0.0001 for each group; ﬁgure 4A,B). Denosumab groups
also signiﬁcantly increased BMD at both sites compared with
the placebo group regardless of glucocorticoid use (p<0.0001
for each subgroup; see online supplementary table S1 and S2).
Denosumab signiﬁcantly decreased the concentration of
CTX-I and PINP compared with placebo at all-time points
(p<0.0001 for each group; see online supplementary ﬁgure S4
and S5). The percent change of the COMP from the baseline in
the denosumab groups showed the same tendency as that in the
placebo group (see online supplementary ﬁgure S6). On the
other hand, denosumab signiﬁcantly decreased CTX-II/Cre con-
centrations from the baseline at 1 month relative to placebo
(p<0.0001 for each group; see online supplementary ﬁgure S7).
Safety
Patient incidence of adverse events was generally comparable
among treatment groups (table 2).
No cases of atypical femoral fracture (AFF) or osteonecrosis
of the jaw were reported. One asymptomatic mild serum
calcium decrease was reported in Q3M as an adverse event. No
trends were noted in blood and urine tests, other than decreases
in serum albumin-adjusted calcium, phosphorus and total alka-
line phosphatase in denosumab groups. Average values of serum
albumin-adjusted calcium at 6 and 12 months in Q6M returned
Figure 1 Patient disposition. DMAb, denosumab; IP, investigational product; Q2M, every 2 months; Q3M, every 3 months; Q6M, every 6 months.
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toward the baseline level. While the calcium level in Q2M and
Q3M tended to recover toward the baseline, a low level was
sustained at 6 and 12 months. All mean and median values in
albumin-adjusted calcium were within the normal range (data
not shown). No antibodies against denosumab were detected.
Pharmacokinetics
In Q6M, trough serum denosumab concentrations reached
below the lower limit of quantiﬁcation in many subjects
(see online supplementary ﬁgure S8). Both Q3M and Q2M
achieved a steady-state plasma level of denosumab within
6 months. Based on AUC, no accumulation was observed in
Q6M (see online supplementary table S3), whereas approxi-
mately 1.3-fold and 1.7-fold accumulations were observed at a
steady state (6 months) in Q3M and Q2M, respectively. AUClast
at a steady state were generally comparable across all denosumab
groups.
DISCUSSION
Denosumab signiﬁcantly inhibited the increase in the modiﬁed
Sharp erosion score compared with the placebo. While direct
comparison between our study and the previous study8 is
Table 1 Baseline demographics and characteristics
Denosumab
Placebo (N=88) 60 mg Q6M (N=85) 60 mg Q3M (N=82) 60 mg Q2M (N=85) Total (N=340)
Gender: female 76 (86.4%) 65 (76.5%) 59 (72.0%) 66 (77.6%) 266 (78.2%)
Age (years) 57.0±10.57 54.4±10.57 52.0±11.65 54.6±10.51 54.5±10.92
≥65 26 (29.5%) 11 (12.9%) 10 (12.2%) 16 (18.8%) 63 (18.5%)
BMI (kg/m2) 22.08±3.27 22.31±3.65 22.21±3.14 23.86±3.46 22.61±3.45
Osteoporosis* 23 (26.1%) 12 (14.1%) 10 (12.2%) 12 (14.1%) 57 (16.8%)
Duration of RA (years) 2.31±1.34 2.16±1.31 2.26±1.27 2.25±1.40 2.25±1.33
RF status positive 60 (68.2%) 59 (69.4%) 56 (68.3%) 57 (67.1%) 232 (68.2%)
Anti-CCP positive 66 (75.0%) 70 (82.4%) 64 (78.0%) 65 (76.5%) 265 (77.9%)
Modified total Sharp score (0–448) 13.56±24.03 11.43±14.48 10.02±14.03 12.74±16.57 11.97±17.81
Modified Sharp erosion score (0–280) 6.61±10.35 6.39±7.77 5.95±6.75 7.41±8.68 6.60±8.50
Modified Sharp JSN score (0–168) 6.94±14.29 5.04±8.31 4.07±8.06 5.33±8.70 5.37±10.24
Swollen joint count (0–66) 10.50±5.93 8.89±4.16 10.51±4.63 10.19±4.71 10.02±4.94
Tender joint count (0–68) 9.90±9.67 8.00±7.37 8.15±7.34 8.33±7.77 8.61±8.12
DAS28-CRP 3.95±0.99 3.63±1.02 3.79±1.03 3.75±0.93 3.78±1.00
Remission 8 (9.1%) 14 (16.5%) 10 (12.2%) 6 (7.1%) 38 (11.2%)
Low 11 (12.5%) 14 (16.5%) 13 (15.9%) 21 (24.7%) 59 (17.4%)
Moderate 59 (67.0%) 50 (58.8%) 51 (62.2%) 54 (63.5%) 214 (62.9%)
High 10 (11.4%) 7 (8.2%) 8 (9.8%) 4 (4.7%) 29 (8.5%)
CRP (mg/dL) 0.75±1.24 0.52±0.92 0.61±1.17 0.60±1.08 0.62±1.11
HAQ-DI (0–3) 0.47±0.52 0.39±0.45 0.32±0.38 0.35±0.39 0.38±0.44
MTX weekly dose (mg) 7.61±1.76 7.98±2.01 8.40±2.19 8.25±2.00 8.05±2.01
Glucocorticoid use 37 (42.0%) 36 (42.4%) 37 (45.1%) 37 (43.5%) 147 (43.2%)
Amount of glucocorticoid (mg/day) 3.78±2.31 3.90±2.27 3.68±1.70 4.03±2.04 3.85±2.08
NSAIDs use 64 (72.7%) 61 (71.8%) 60 (73.2%) 68 (80.0%) 253 (74.4%)
DMARDs use† 22 (25.0%) 18 (21.2%) 15 (18.3%) 22 (25.9%) 77 (22.6%)
Lumbar spine BMD by machine type (g/cm2)
Hologic‡ 0.87±0.18 0.90±0.17 0.92±0.16 0.92±0.16 0.90±0.17
Lunar‡ 1.04±0.18 1.05±0.21 1.11±0.21 1.06±0.19 1.07±0.19
Total hip BMD by machine type (g/cm2)
Hologic‡ 0.76±0.14 0.80±0.13 0.80±0.13 0.83±0.13 0.80±0.13
Lunar‡ 0.83±0.15 0.84±0.13 0.87±0.16 0.86±0.16 0.85±0.15
CTX-I (ng/mL)§ 0.38 (0.26, 0.53) 0.36 (0.21, 0.51) 0.36 (0.22, 0.56) 0.37 (0.26, 0.65) 0.37 (0.23, 0.56)
PINP (μg/L)§ 46.60 (30.25, 62.20) 42.90 (30.00, 58.30) 42.95 (31.60, 57.40) 46.40 (33.30, 64.50) 44.35 (31.45, 60.30)
COMP (U/L)§ 8.05 (6.60, 10.30) 8.10 (6.60, 9.70) 8.20 (6.70, 9.60) 8.40 (7.10, 10.30) 8.20 (6.60, 9.95)
CTX-II (ng/mmol Cre)§ 361.50
(205.50, 649.50)
304.50
(183.50, 497.00)
325.00
(191.00, 501.00)
320.00
(210.00, 661.00)
324.00
(199.00, 537.00)
N=number of patients who received ≥1 dose of investigational product and had a baseline and at least 1 postbaseline measurement of the radiograph score.
Values are mean±SD or n (%) unless otherwise indicated.
*Osteoporosis was diagnosed by the investigators at each site.
†Excluding methotrexate.
‡Hologic machines use: 65, 58, 61 and 57 patients; Lunar machines use: 23, 27, 21 and 28 patients. Placebo, Q6M, Q3M and Q2M, respectively.
§Values are median (quartile 1, quartile 3).
BMD, bone mineral density; BMI, bone mass index; CCP, cyclic citrullinated peptide; COMP, cartilage oligomeric matrix protein; Cre, creatinine; CRP, C-reactive protein; CTX-I,
C-telopeptide of type I collagen; CTX-II, C-telopeptide of type II collagen; DAS, disease activity score; DMARDs, disease-modifying antirheumatic drugs; HAQ-DI, Health Assessment
Questionnaire Disability Index; JSN, joint space narrowing; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; PINP, N-propeptide of type I collagen; Q2M, every
2 months; Q3M, every 3 months; Q6M, every 6 months; RA, rheumatoid arthritis; RF, rheumatoid factor.
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Figure 2 Mean changes from the
baseline at 12 months in the
radiographic score by the van der
Heijde-modiﬁed Sharp method. (A)
Modiﬁed Sharp erosion score. (B)
Modiﬁed Sharp joint space narrowing
score. (C) Modiﬁed total Sharp score.
N=number of patients who received
≥1 dose of investigational product and
had a baseline and at least 1
postbaseline measurement of the
radiograph score. Mean (95% CI).
Missing values were imputed using
linear extrapolation/interpolation.
*p<0.025 vs placebo, Shirley–Williams
test with α=0.025 one-sided versus
placebo. (B) Because the change in
score of the highest dose group of
Q2M was not statistically signiﬁcant,
following statistical comparisons were
not performed. (C) Because the change
in score of Q3M was not statistically
signiﬁcant, statistical comparison at
6 months between placebo and Q6M
was not performed. Q2M, every
2 months; Q3M, every 3 months; Q6M,
every 6 months.
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difﬁcult because the patients’ backgrounds are different (such as
mean RA duration is about 2 and 11 years, respectively), both
of these studies showed that denosumab inhibited the bone
destruction. Shorter dosing interval regimens of denosumab
showed a numerical trend for better inhibition of bone destruc-
tion, while signiﬁcant differences among denosumab groups
were not conﬁrmed. However, the trial was not powered to
detect differences between doses. The proportion of the patients
with no increase of the modiﬁed Sharp erosion score also
increased with shorter dosing intervals. These small differences
among denosumab groups may expand in longer-term observa-
tion. The mean trough concentration of denosumab increased
with shorter dosing regimens. These results may indicate that
higher trough concentrations of denosumab result in less pro-
gression of bone erosion.
Denosumab groups showed no signiﬁcant difference compared
with the placebo group in almost all parameters of disease activity.
Also, no signiﬁcant difference was observed in any component of
ACR response between the denosumab groups and the placebo
group (see online supplementary table S4–S9). These results indi-
cate that denosumab may have no effect on RA disease activity.
These results were consistent with a previous RA study.8 The
decreasing trend of DAS28-CRP was observed in all groups. The
change of amount of methotrexate from baseline to 12 months
was small, and the percentage of other added disease-modifying
antirheumatic drugs (DMARDs) to methotrexate or increasing the
amount of DMARDs was also small (data not shown). While
patients took the methotrexate for at least 8 weeks from PI admin-
istration, this duration may not be long enough to achieve the
maximum effect at baseline. Therefore, continuous background
treatment together with better compliance during the RCT might
contribute to the DAS28-CRP decrease.
No signiﬁcant difference in HAQ-DI was observed between
the denosumab groups and placebo group. Joint destruction
Figure 3 Cumulative probability plots of changes from the baseline
at 12 months. (A) Modiﬁed Sharp erosion score. (B) Modiﬁed Sharp
joint space narrowing score. (C) Modiﬁed total Sharp score. N=number
of patients who received ≥1 dose of investigational product and had a
baseline and at least 1 postbaseline measurement of the radiograph
score. Q2M, every 2 months; Q3M, every 3 months; Q6M, every
6 months.
Figure 4 Percent change of BMD from the baseline. (A) Lumbar spine
and (B) total hip. N=number of patients who received ≥1 dose of
investigational product and had a baseline and at least 1 post-baseline
measurement. *p<0.0001 vs placebo, based on repeated measures
model adjusting for treatment, visit, baseline value, randomised strata
(4 strata from the combination of baseline use of glucocorticoid and
baseline rheumatoid factor) and treatment-by-visit interaction. Least
square mean (95% CI). BMD, bone mineral density; Q2M, every
2 months; Q3M, every 3 months; Q6M, every 6 months.
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assessed by modiﬁed TSS is related to functional disability,
which was conﬁrmed in long-term observations.16 However,
this relationship is weak in the short term. Our study was
limited to 12 months. Therefore, detecting the difference in
HAQ-DI was considered difﬁcult. However, all denosumab
groups showed a signiﬁcantly inhibited increase of the modi-
ﬁed TSS at 12 months compared with the placebo group.
Therefore, denosumab is considered to have a potential to con-
tribute to maintaining physical function with long-term
treatment.
BMD increased signiﬁcantly at all sites in all denosumab
groups compared with the placebo group. While there was no
signiﬁcant difference among denosumab groups in BMD
change at the TH, signiﬁcant differences in BMD change at
the LS were conﬁrmed between Q2M and Q6M and between
Q2M and Q3M at 6 months (p=0.0063 and 0.0276, respect-
ively) and 12 months (p=0.0004 and 0.0477, respectively).
These results indicate that changes in BMD may be easier to
detect in areas rich in trabecular bone than areas richer in
cortical bone.
Denosumab increased BMD in patients with RA regardless of
glucocorticoid use. Thus, denosumab is expected to be a thera-
peutic option for preventing bone loss in patients with RA
regardless of glucocorticoid treatment.
Trend of the BTMs change is consistent with previous
studies.17 18 Result of COMP seems to be consistent with the
result of the modiﬁed Sharp JSN score change. However,
CTX-II/Cre was suppressed in the denosumab groups compared
with the placebo group. Non-clinical data suggest that osteoclasts
relate to the progression of bone erosion in the subchondral bone
and destruction of the mineralised cartilage.19–21 Therefore, our
results raise the possibility that prevention of this destruction by
denosumab may lead to secondary inhibition of cartilage destruc-
tion. However, this study showed some discrepancies. Also,
CTX-II is usually used as a cartilage marker, while it sometimes is
regarded as a BTM.22 23 Thus, additional research on the cartil-
age markers may be needed.
Twelve months of treatment with denosumab was well tolerated
in Japanese patients with RA. The safety proﬁles of denosumab
groups were generally comparable with the placebo group and con-
sistent with previous studies.8 17 18 24 While AFF was not reported,
both the Q3M and Q2M groups maintained the chronic decrease
of BTMs. We may need longer term observation to conﬁrm it.
Insufﬁcient inhibition of structural joint damage by DMARDs
was reported despite clinical improvement.25–27 Some patients
with an inadequate response to DMARDs are treated with biolo-
gics. However, many of these patients cannot move to biologic
therapy for a variety of reasons. Our study indicates that addition
of denosumab to background methotrexate treatment has poten-
tial to be a new therapeutic option for prevention of joint
damage in patients with RAwith risk factors of joint destruction.
Limitations of this study include the relatively short duration
of the treatment and the relatively small number of patients.
Also, this study was not designed completely based on the ‘treat
to target’ principle28 because the objectives of this study are to
evaluate efﬁcacy and safety of denosumab in patients with RA.
In conclusion, our study demonstrated that denosumab inhib-
ited the progression of bone erosion, increased BMDs and was
generally well tolerated in Japanese patients with RA on metho-
trexate. Addition of denosumab to background methotrexate
treatment has potential to be a new therapeutic option for
patients with RAwith risk factors for joint destruction.
Author afﬁliations
1Division of Rheumatology, Department of Internal Medicine, Keio University School
of Medicine, Tokyo, Japan
2First Department of Internal Medicine, University of Occupational and
Environmental Health, Kitakyushu, Japan
3Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine,
Aichi, Japan
4Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Table 2 Summary of adverse events
Denosumab
Placebo (N=88) 60 mg Q6M (N=86) 60 mg Q3M (N=85) 60 mg Q2M (N=87)
All adverse events 73 (83.0%) 69 (80.2%) 65 (76.5%) 82 (94.3%)
Serious adverse events 9 (10.2%) 4 (4.7%) 6 (7.1%) 8 (9.2%)
Treatment-related adverse events 16 (18.2%) 16 (18.6%) 12 (14.1%) 18 (20.7%)
Treatment-related serious adverse events 2 (2.3%) 1 (1.2%) 2 (2.4%) 0
Death 0 0 0 0
Any adverse event in ≥5% of patients in any treatment group
Nasopharyngitis 23 (26.1%) 21 (24.4%) 20 (23.5%) 28 (32.2%)
Hepatic function abnormal 14 (15.9%) 7 (8.1%) 9 (10.6%) 17 (19.5%)
Stomatitis 5 (5.7%) 6 (7.0%) 5 (5.9%) 9 (10.3%)
Upper respiratory tract inflammation 5 (5.7%) 4 (4.7%) 10 (11.8%) 6 (6.9%)
Pharyngitis 7 (8.0%) 7 (8.1%) 4 (4.7%) 5 (5.7%)
Back pain 2 (2.3%) 5 (5.8%) 3 (3.5%) 6 (6.9%)
Bronchitis 3 (3.4%) 2 (2.3%) 5 (5.9%) 5 (5.7%)
Dental caries 3 (3.4%) 3 (3.5%) 5 (5.9%) 4 (4.6%)
Eczema 2 (2.3%) 2 (2.3%) 3 (3.5%) 6 (6.9%)
Constipation 3 (3.4%) 5 (5.8%) 1 (1.2%) 3 (3.4%)
Periodontitis 5 (5.7%) 1 (1.2%) 5 (5.9%) 2 (2.3%)
Gastritis 2 (2.3%) 0 5 (5.9%) 2 (2.3%)
Hypertension 5 (5.7%) 1 (1.2%) 1 (1.2%) 1 (1.1%)
Data are number or number (%). N=number of patients who received ≥1 dose of investigational product. Classifications of adverse events are based on the Medical Dictionary for
Regulatory Activities. Only includes treatment-emergent adverse events. Preferred terms are sorted by descending order of pooled frequency in the denosumab groups.
Q2M, every 2 months; Q3M, every 3 months; Q6M, every 6 months.
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